Zacks: Athersys, Inc. (ATHX) Given Average Rating of “Strong Buy” by Analysts
Shares of Athersys, Inc. (NASDAQ:ATHX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price objective of $9.00 for the company and are anticipating that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given Athersys an industry rank of 159 out of 265 based on the ratings given to its competitors.
Several analysts have recently commented on the stock. Maxim Group set a $9.00 price objective on shares of Athersys and gave the stock a “buy” rating in a research report on Tuesday, May 16th. Zacks Investment Research downgraded shares of Athersys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 9th. William Blair reaffirmed an “outperform” rating on shares of Athersys in a research report on Tuesday, March 28th. Finally, Needham & Company LLC assumed coverage on shares of Athersys in a research report on Tuesday, February 7th. They set a “buy” rating and a $7.00 price objective for the company.
Athersys (NASDAQ:ATHX) remained flat at $1.45 on Wednesday. The company had a trading volume of 246,589 shares. The firm’s market capitalization is $161.41 million. The firm’s 50 day moving average is $1.48 and its 200 day moving average is $1.43. Athersys has a 12 month low of $1.02 and a 12 month high of $2.60.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $0.45 million. Athersys had a negative net margin of 17.12% and a negative return on equity of 22.82%. The company’s quarterly revenue was down 90.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.06 EPS. Equities analysts predict that Athersys will post ($0.26) EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its position in shares of Athersys by 4.8% in the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 2,800 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Athersys by 17.2% in the first quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 9,019 shares in the last quarter. Oxford Asset Management purchased a new position in shares of Athersys during the fourth quarter worth about $105,000. TFS Capital LLC purchased a new position in shares of Athersys during the first quarter worth about $149,000. Finally, NEXT Financial Group Inc boosted its position in shares of Athersys by 14.4% in the third quarter. NEXT Financial Group Inc now owns 106,100 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 13,350 shares in the last quarter. Institutional investors own 17.24% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/24/zacks-athersys-inc-athx-given-average-rating-of-strong-buy-by-analysts.html.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.